^
    Apply
    Study to Evaluate D-1553 in Subjects With Solid Tumors (KEYNOTE-C15) (NCT04585035)
    Phase 1/2
    InventisBio Co., Ltd
    Active, not recruiting
    Last update posted :
    10/14/2024
    Initiation :
    10/02/2020
    Primary completion :
    04/30/2024
    Completion :
    02/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • garsorasib (D-1553)
    GH21 Combined With D-1553 With Advanced Solid Tumors (NCT06435455)
    Phase 1/2
    Suzhou Genhouse Bio Co., Ltd.
    Not yet recruiting
    Last update posted :
    05/31/2024
    Initiation :
    07/01/2024
    Primary completion :
    09/30/2027
    Completion :
    12/31/2027
    KRAS
    |
    garsorasib (D-1553) • HBI-2376
    a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (NCT06166836)
    Phase 1/2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    10/12/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    Study to Evaluate D-1553 in Subjects With Lung Cancer (NCT05383898)
    Phase 1/2
    InventisBio Co., Ltd
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    03/16/2021
    Primary completion :
    11/17/2023
    Completion :
    06/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553)
    Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (NCT05379946)
    Phase 1/2
    InventisBio Co., Ltd
    Recruiting
    Last update posted :
    10/18/2023
    Initiation :
    10/12/2022
    Primary completion :
    06/30/2024
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer (NCT05492045)
    Phase 1b/2
    InventisBio Co., Ltd
    Recruiting
    Last update posted :
    04/25/2023
    Initiation :
    09/13/2022
    Primary completion :
    04/01/2024
    Completion :
    12/01/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553)